Making cell replacement therapies effective and scalable 

Scientists developed hypoimmune induced pluripotent stem cells to reduce the risk of immune rejection and immunogenicity during cell therapy.

Using induced pluripotent stem cells (iPSCs) for cell therapy comes with significant limitations, including the potential for immune rejection in patients receiving allogeneic cell therapy and challenges in autologous cell transplant standardization. To overcome these barriers, scientists made iPSCs that evade the innate and adaptive immune systems and enable consistent and universally compatible iPSCs.

Download this research summary from Bio-Techne to learn how scientists developed immunologically undetectable iPSCs with the potential for mass production and differentiation into functional cells. 

Sponsored by